# Ruxolitinib and Decitabine for High Risk Hematological Malignancies

> **NCT04582604** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chinese PLA General Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Peripheral Blood Stem Cell Transplantation

## Interventions

- **DRUG:** modified By/Cy conditioning regimen intensified by Ruxolitinib and Decitabine

## Key facts

- **NCT ID:** NCT04582604
- **Lead sponsor:** Chinese PLA General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-09-01
- **Primary completion:** 2023-09-01
- **Final completion:** 2025-09-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-10-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04582604

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04582604, "Ruxolitinib and Decitabine for High Risk Hematological Malignancies". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04582604. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*